Literature DB >> 1169115

Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.

F M Sirotnak, R C Donsback.   

Abstract

A greater persistence of unbound (exchangeable) drug in tumor cells versus drug-limiting normal tissue (proliferating epithelium of small intestine) correlates with the therapeutic effects of various antifolates against a group of murine tumors. After approsimate equimolar doses (3 mg/kg i.p.) of methotrexate (MTX) methasquin (MQ), aminopterin, and N-([2,4-diamino-5-chloro-6-quinazolinyl) methyl]-amino)benzol)-L-glutamate (5-Cl-deaza-AM), total accumulation in small intestine was vie- to eight-fold greater than the dihydrofolate reductase content. Free drug persisted for less than 4 hr (MTX), 16 hr (MQ), 30 hr (aminopterin),and 48 hr (5-Cl-deaza-AM). Overall drug accumulation in L121O cells was greater (12- to 40-fold enzyme level), and drug persistence above enzyme level was more prolonged in the case of MTX (24 hr),MQ (32 hr), and 5-Cl-deaza-AM (greater than 48 hr). Persistence of aminopterin was similar to that seen in small intestine. After the same dose of each drug s.c., the results were similar in small intestine. In L121o cells, however, the total drug accumulation was much lower, but the relative persistence of each was similar to that seen after an i.p. dose. After a single optimal therapeutic dose (3, 0.75, 0.3, and 0.1 mg/kg i.p. for MTX, MQ, aminopterin, and 5-Cl-deaza-AM every other day), accumulation of each drug in for no more than 4 hr. In L121O cells, maximal accumulation of each drug also varied, but persistence differed in accordance with the relative therapeutic effectiveness of each (9 hr for 5-Cl-deaza-AM, 12 hr for aminopterin, and more than 20 hr for MTX amd MQ).

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1169115

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Selective uptake and retention of anticancer agents by sensitive cells.

Authors:  D L Hill; J A Montgomery
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Pharmacokinetics of methotrexate in leukemia cells: effect of dose and mode of injection.

Authors:  J M Weissbrod; R K Jain; F M Sirotnak
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

3.  Selective killing of preneoplastic and neoplastic cells by methotrexate with leucovorin.

Authors:  M Chow; H Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

4.  New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties.

Authors:  F M Sirotnak; J I DeGraw; D M Moccio; L L Samuels; L J Goutas
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.

Authors:  N Lena; A M Imbert; T Pignon; R Favre; G Meyer; J P Cano; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.

Authors:  F M Sirotnak; J I DeGraw; F A Schmid; L J Goutas; D M Moccio
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells.

Authors:  S Cabral; S Leis; L Bover; M Nembrot; J Mordoh
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  The effect of chemotherapy on occult metastases after surgical removal of a non-immunogenic mouse carcinoma.

Authors:  T Zebro; E A Wright
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.